Expert panel consensus recommendations on the utilization of nebulized budesonide for managing asthma and COPD in both stable and exacerbation stages in Thailand

References

• World Health Organization. Chronic respiratory diseases. https://www.who.int/health-topics/chronic-respiratory-diseases#tab=tab_1
   Google Scholar
• Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015;1(1):15025. doi:10.1038/nrdp.2015.25.
   PubMed Web of Science ®Google Scholar
• McIntyre A, Busse WW. Asthma exacerbations: the Achilles heel of asthma care. Trends Mol Med. 2022;28(12):1112–1127. doi:10.1016/j.molmed.2022.09.001.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023. https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf.
   Google Scholar
• Soremekun S, Heaney LG, Skinner D, Bulathsinhala L, Carter V, Chaudhry I, Hosseini N, Eleangovan N, Murray R, Tran TN, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study. Thorax. 2023;78(7):643–652. doi:10.1136/thorax-2021-217032.
   PubMed Web of Science ®Google Scholar
• Ansari SF, Memon M, Kumar R, Rizwan A. Risk factors associated with frequent acute exacerbations of asthma. Cureus. 2020;12(10):e11090. doi:10.7759/cureus.11090.
   PubMed Web of Science ®Google Scholar
• DiMango E, Rogers L, Reibman J, Gerald LB, Brown M, Sugar EA, Henderson R, Holbrook JT. Risk factors for asthma exacerbation and treatment failure in adults and adolescents with well-controlled asthma during continuation and step-down therapy. Ann Am Thorac Soc. 2018;15(8):955–961. doi:10.1513/AnnalsATS.201711-886OC.
   PubMed Web of Science ®Google Scholar
• Sims EJ, Price D, Haughney J, Ryan D, Thomas M. Current control and future risk in asthma management. Allergy Asthma Immunol Res. 2011;3(4):217–225. doi:10.4168/aair.2011.3.4.217.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J. 2019;54(3):1900900. doi:10.1183/13993003.00900-2019.
   PubMed Web of Science ®Google Scholar
• Elsey L, Allen D. Management of acute exacerbations of airways disease: advice for the non-respiratory physician. Clin Med. 2021;21(6):e567–e70. doi:10.7861/clinmed.2021-0649.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD. 2024. https://goldcopd.org/2024-gold-report/.
   Google Scholar
• Ruvuna L, Sood A. Epidemiology of Chronic Obstructive Pulmonary Disease. Clin Chest Med. 2020;41(3):315–327. doi:10.1016/j.ccm.2020.05.002.
   PubMed Web of Science ®Google Scholar
• Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, Franssen FME, Humbert M, Hurst JR, O’Donnell D, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251–1258. doi:10.1164/rccm.202108-1819PP.
   PubMed Web of Science ®Google Scholar
• Jeyachandran V, Hurst JR. Advances in chronic obstructive pulmonary disease: management of exacerbations. Br J Hosp Med (Lond). 2022;83(7):1–7. doi:10.12968/hmed.2022.0275.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. How corticosteroids control inflammation: quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245–254. doi:10.1038/sj.bjp.0706736.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139(5 Pt 1):359–370. doi:10.7326/0003-4819-139-5_part_1-200309020-00012.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876. doi:10.1056/NEJMoa1715274.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Rodrigo C. Corticosteroids in the emergency department therapy of acute adult asthma: an evidence-based evaluation. Chest. 1999;116(2):285–295. doi:10.1378/chest.116.2.285.
   PubMed Web of Science ®Google Scholar
• Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001;(1):CD002178. doi:10.1002/14651858.CD002178.
   PubMedGoogle Scholar
• Afilalo M, Guttman A, Colacone A, Dankoff J, Tselios C, Stern E, Wolkove N, Kreisman H. Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department: a randomized clinical trial. Ann Emerg Med. 1999;33(3):304–309. doi:10.1016/s0196-0644(99)70367-7.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998;157(3 Pt 1):698–703. doi:10.1164/ajrccm.157.3.9704022.
   PubMed Web of Science ®Google Scholar
• Edmonds ML, Milan SJ, Camargo CA, Jr., Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12(12):CD002308. doi:10.1002/14651858.CD002308.pub2.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. https://www.nice.org.uk/guidance/ng115.
   Google Scholar
• Stanbury RM, Graham EM. Systemic corticosteroid therapy–side effects and their management. Br J Ophthalmol. 1998;82(6):704–708. doi:10.1136/bjo.82.6.704.
   PubMed Web of Science ®Google Scholar
• Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–16. doi:10.1164/ajrccm.150.1.8025735.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Guerrero M, Menéndez R, Huerta A, Martinez R, Gimeno A, Soler N, Torres A. Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. Respir Care. 2014;59(10):1550–1559. doi:10.4187/respcare.03036.
   PubMed Web of Science ®Google Scholar
• Trikamjee T, Comberiati P, Peter J. Pediatric asthma in developing countries: challenges and future directions. Curr Opin Allergy Clin Immunol. 2022;22(2):80–85. doi:10.1097/ACI.0000000000000806.
   PubMed Web of Science ®Google Scholar
• Boonsawat W, Charoenphan P, Kiatboonsri S, Wongtim S, Viriyachaiyo V, Pothirat C, Thanomsieng N. Survey of asthma control in Thailand. Respirology. 2004;9(3):373–378. doi:10.1111/j.1440-1843.2004.00584.x.
   PubMed Web of Science ®Google Scholar
• Dejsomritrutai W, Nana A, Chierakul N, Tscheikuna J, Sompradeekul S, Ruttanaumpawan P, Charoenratanakul S. Prevalence of bronchial hyperresponsiveness and asthma in the adult population in Thailand. Chest. 2006;129(3):602–609. doi:10.1378/chest.129.3.602.
   PubMed Web of Science ®Google Scholar
• Boonsawat W, Thompson PJ, Zaeoui U, Samosorn C, Acar G, Faruqi R, Poonnoi P. Survey of asthma management in Thailand - the asthma insight and management study. Asian Pac J Allergy Immunol. 2015;33(1):14–20. doi:10.12932/AP0473.33.1.2015.
   PubMed Web of Science ®Google Scholar
• Kitjakrancharoensin P, Yasan K, Hongyantarachai K, Ratanachokthorani K, Thammasarn J, Kuwuttiwai D, Ekanaprach T, Jittakarm R, Nuntapravechpun R, Hotarapavanon S, et al. Prevalence and risk factors of chronic obstructive pulmonary disease among agriculturists in a rural community, Central Thailand. Int J Chron Obstruct Pulmon Dis. 2020;15:2189–2198. doi:10.2147/COPD.S262050.
   PubMed Web of Science ®Google Scholar
• Pothirat C, Phetsuk N, Deesomchok A, Theerakittikul T, Bumroongkit C, Liwsrisakun C, Inchai J. Clinical characteristics, management in real world practice and long-term survival among COPD patients of Northern Thailand COPD club members. J Med Assoc Thai. 2007;90(4):653–662. Cited: in:: PMID: 17487118.
   PubMedGoogle Scholar
• Barjaktarevic IZ, Milstone AP. Nebulized therapies in COPD: past, present, and the future. Int J Chron Obstruct Pulmon Dis. 2020;15:1665–1677. doi:10.2147/COPD.S252435.
   PubMed Web of Science ®Google Scholar
• Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406. doi:10.1016/j.jclinepi.2010.07.015.
   PubMed Web of Science ®Google Scholar
• Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726–735. doi:10.1016/j.jclinepi.2013.02.003.
   PubMed Web of Science ®Google Scholar
• Otulana BA, Varma N, Bullock A, Higenbottam T. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Respir Med. 1992;86(2):105–108. doi:10.1016/s0954-6111(06)80224-6.
   PubMed Web of Science ®Google Scholar
• Ediger D, Coşkun F, Kunt Uzaslan E, Gürdal Yüksel E, Karadağ M, Ege E, Gözü O. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks. Tuberk Toraks. 2006;54(2):128–136. Cited: in:: PMID: 16924568.
   PubMedGoogle Scholar
• Shah RV, Amin M, Sangwan S, Smaldone GC. Steroid effects on mucociliary clearance in outpatient asthma. J Aerosol Med. 2006;19(2):208–220. doi:10.1089/jam.2006.19.208.
   PubMedGoogle Scholar
• Murphy K, Noonan M, Silkoff PE, Uryniak T. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler. Clin Ther. 2007;29(6):1013–1026. doi:10.1016/j.clinthera.2007.06.005.
   PubMed Web of Science ®Google Scholar
• Chian CF, Tsai CL, Wu CP, Chiang CH, Su WL, Chen CW, Perng WC. Five-day course of budesonide inhalation suspension is as effective as oral prednisolone in the treatment of mild to severe acute asthma exacerbations in adults. Pulm Pharmacol Ther. 2011;24(2):256–260. doi:10.1016/j.pupt.2010.07.001.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Kardos P, Hofmann T, Canisius S, Scheuch G, Muellinger B, Nocker K, Menz G, Rabe KF. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. Eur Respir J. 2015;45(5):1273–1282. doi:10.1183/09031936.00152014.
   PubMed Web of Science ®Google Scholar
• Sheikh-Motahar-Vahedi H, Habibi-Samadi M, Vahidi E, Saeedi M, Momeni M. Nebulized Budesonide vs. Placebo in Adults with Asthma Attack; a Double Blind Randomized Placebo-Controlled Clinical Trial. Adv J Emerg Med. 2019;3(1):e4. doi:10.22114/AJEM.v0i0.112.
   PubMedGoogle Scholar
• Ito K, Kanemitsu Y, Fukumitsu K, Inoue Y, Nishiyama H, Yamamoto S, Kitamura Y, Kurokawa R, Takeda N, Fukuda S, et al. The impact of budesonide inhalation suspension for asthma hospitalization: in terms of length of stay, recovery time from symptoms, and hospitalization costs. Allergol Int. 2020;69(4):571–577. doi:10.1016/j.alit.2020.04.003.
   PubMed Web of Science ®Google Scholar
• Marghli S, Bouhamed C, Sghaier A, Chebbi N, Dlala I, Bettout S, Belkacem A, Kbaier S, Jerbi N, Bellou A. Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial. BMC Emerg Med. 2022;22(1):134. doi:10.1186/s12873-022-00691-9.
   PubMed Web of Science ®Google Scholar
• Morice AH, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther. 1996;60(6):675–678. doi:10.1016/S0009-9236(96)90216-7.
   PubMed Web of Science ®Google Scholar
• Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698–703. doi:10.1164/ajrccm.165.5.2109093.
   PubMed Web of Science ®Google Scholar
• Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig. 2003;23(1):55–62. doi:10.2165/00044011-200323010-00007.
   PubMed Web of Science ®Google Scholar
• Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660–667. doi:10.1183/09031936.00073506.
   PubMed Web of Science ®Google Scholar
• Yilmazel Ucar E, Araz O, Meral M, Sonkaya E, Saglam L, Kaynar H, Gorguner AM, Akgun M. Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial. Med Sci Monit. 2014;20:513–520. doi:10.12659/MSM.890210.
   PubMed Web of Science ®Google Scholar
• Sun X, He Z, Zhang J, Deng J, Bai J, Li M, Zhong X. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulm Pharmacol Ther. 2015;31:111–116. doi:10.1016/j.pupt.2014.09.004.
   PubMed Web of Science ®Google Scholar
• Ding Z, Li X, Lu Y, Rong G, Yang R, Zhang R, Wang G, Wei X, Ye Y, Qian Z, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2016;121:39–47. doi:10.1016/j.rmed.2016.10.013.
   PubMed Web of Science ®Google Scholar
• Jiang DH, Wang X, Liu LS, Ji DD, Zhang N. The effect of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of COPD in acute exacerbation period on circulating levels of inflammation and prognosis. Eur Rev Med Pharmacol Sci. 2017;21(22):5211–5216. doi:10.26355/eurrev_201711_13843.
   PubMed Web of Science ®Google Scholar
• Hashemian SM, Mortaz E, Jamaati H, Bagheri L, Mohajerani SA, Garssen J, Movassaghi M, Barnes PJ, Hill NS, Adcock IM. Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: association with inflammatory mediators and cells. J Crit Care. 2018;44:161–167. doi:10.1016/j.jcrc.2017.10.045.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Zhang J, Ma LJ, Chen P, Huang M, Ou XM, Zhao ZW, Jiang SJ, Cao J, Yao W. Clinical outcomes of using nebulized budesonide as the initial treatment for acute exacerbations of chronic obstructive pulmonary disease: a post-hoc analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:2725–2731. doi:10.2147/COPD.S196615.
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhu J, Liu Y, Li Y, Liu W, Zhang M, Chen B, Zhu S. Optimization of nebulized budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:409–415. doi:10.2147/COPD.S235125.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Y, Zhang J, Yao W, Yang J, Li F, Lu L, Zheng J, Han X, Xu JF. Comparison of the clinical outcomes between nebulized and systemic corticosteroids in the treatment of acute exacerbation of COPD in China (CONTAIN Study): a post hoc analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2343–2353. doi:10.2147/COPD.S255475.
   PubMed Web of Science ®Google Scholar
• Aghili M, Vahidi E, Mohammadrezaei N, Mirrajei T, Abedini A. Effectivness of nebulized budesonide for COPD exacerbation management in emergency department; a randomized clinical trial. Arch Acad Emerg Med. 2020;8(1):e85.
   PubMedGoogle Scholar
• Nguyen D, Larson T, Leinbach H, Guthrie E. Systemic steroid and nebulized budesonide combination therapy versus systemic steroid monotherapy in patients with acute exacerbation of chronic obstructive pulmonary disease in a community hospital: a retrospective cohort study. Hosp Pharm. 2021;56(6):786–791. doi:10.1177/0018578720965417.
   PubMed Web of Science ®Google Scholar
• Gu YL, Sun ZX, Sun Y, Wen Y, Guan X, Jiang DL, Cheng C, Gu H. A real-world cost-effectiveness analysis of nebulized budesonide and intravenous methylprednisolone in acute exacerbation of chronic obstructive pulmonary disease. Front Pharmacol. 2022;13:892526. doi:10.3389/fphar.2022.892526.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Lipworth B, Brattsand R. Benefit: risk Profile of Budesonide in Obstructive Airways Disease. Drugs. 2019;79(16):1757–1775. doi:10.1007/s40265-019-01198-7.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380. doi:10.1111/bcp.12637.
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Wollmer P, Selroos O, Borgström L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21(2):247–258. doi:10.1016/j.pupt.2007.08.005.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292–1300. doi:10.1111/j.1398-9995.2008.01750.x.
   PubMed Web of Science ®Google Scholar
• Dalby C, Polanowski T, Larsson T, Borgström L, Edsbäcker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10(1):104. doi:10.1186/1465-9921-10-104.
   PubMedGoogle Scholar
• Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1(5):402–413. doi:10.1016/S2213-2600(13)70072-9.
   PubMed Web of Science ®Google Scholar
• Janson C, Stratelis G, Miller-Larsson A, Harrison TW, Larsson K. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064. doi:10.2147/COPD.S143656.
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-202872.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050. doi:10.1183/09031936.00074905.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23(1):11–33. doi:10.2165/00002018-200023010-00002.
   PubMed Web of Science ®Google Scholar
• Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(39 Suppl):1–34. doi:10.1111/j.1398-9995.1997.tb05047.x.
   PubMed Web of Science ®Google Scholar
• van den Brink KIM, Boorsma M, Staal-van den Brekel AJ, Edsbäcker S, Wouters EF, Thorsson L. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008;66(1):27–35. doi:10.1111/j.1365-2125.2008.03164.x.
   PubMed Web of Science ®Google Scholar
• Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc. 2004;1(3):269–274. doi:10.1513/pats.200402-007MS.
   PubMedGoogle Scholar
• Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26(7):623–630.
   PubMed Web of Science ®Google Scholar
• Ellul-Micallef R, Hansson E, Johansson SA. Budesonide: a new corticosteroid in bronchial asthma. Eur J Respir Dis. 1980;61(3):167–173.
   PubMedGoogle Scholar
• Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325(6):388–392. doi:10.1056/NEJM199108083250603.
   PubMed Web of Science ®Google Scholar
• Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998;101(4 Pt 1):457–463. doi:10.1016/S0091-6749(98)70353-7.
   PubMed Web of Science ®Google Scholar
• Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004;23(4):552–558. doi:10.1183/09031936.04.00076604.
   PubMed Web of Science ®Google Scholar
• Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest. 1995;108(6):1568–1571. doi:10.1378/chest.108.6.1568.
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Wang T, Xu X, Beiko T, Bei H, Zhai S, Drummond MB. Nebulized corticosteroids in the treatment of COPD exacerbations: systematic review, meta-analysis, and clinical perspective. Respir Care. 2018;63(10):1302–1310. doi:10.4187/respcare.06384.
   PubMed Web of Science ®Google Scholar
• Gu YL, Pang J, Sun ZX, Hu J, Sun Y, Wu XW, Guo JJ, Yang GS. Comparative efficacies of nebulized budesonide and systemic corticosteroids in the treatment of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Clin Pharm Ther. 2020;45(3):419–429. doi:10.1111/jcpt.13095.
   PubMed Web of Science ®Google Scholar
• Shang W, Wang G, Wang Y, Han D. The safety of long-term use of inhaled corticosteroids in patients with asthma: A systematic review and meta-analysis. Clin Immunol. 2022;236:108960. doi:10.1016/j.clim.2022.108960.
   PubMed Web of Science ®Google Scholar
• Spantideas N, Drosou E, Bougea A, Assimakopoulos D. Inhaled Corticosteroids and Voice Problems. What Is New? J Voice. 2017;31(3):384 e1–e7. doi:10.1016/j.jvoice.2016.09.002.
   Web of Science ®Google Scholar
• Chalitsios CV, Shaw DE, McKeever TM. Corticosteroids and bone health in people with asthma: A systematic review and meta-analysis. Respir Med. 2021;181:106374. doi:10.1016/j.rmed.2021.106374.
   PubMed Web of Science ®Google Scholar
• Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med. 2001;164(4):521–535. doi:10.1164/ajrccm.164.4.2101050.
   PubMed Web of Science ®Google Scholar
• Kwda A, Gldc P, Baui B, Kasr K, Us H, S W, Kantha L, Ksh S. Effect of long term inhaled corticosteroid therapy on adrenal suppression, growth and bone health in children with asthma. BMC Pediatr. 2019;19(1):411. doi:10.1186/s12887-019-1760-8.
   PubMed Web of Science ®Google Scholar
• Chinese College of Emergency Physicians (CCEP), Emergency Committee of PLA, Beijing Society for Emergency Medicine, and Chinese Emergency Medicine . Expert consensus on nebulization therapy in pre-hospital and in-hospital emergency care. Ann Transl Med. 2019;7:487. doi:10.21037/atm.2019.09.44.
   PubMed Web of Science ®Google Scholar
• Goldstein KM, Ghadimi K, Mystakelis H, Kong Y, Meng T, Cantrell S, Von Isenburg M, Gordon A, Ear B, Gierisch JM, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021;34(3):155–170. doi:10.1089/jamp.2020.1659.
   PubMed Web of Science ®Google Scholar
• Nematollahi AV, Motamed H, Masoumi K, Forouzan A, Nobakht E. Efficacy evaluation of budesonide nebulizer as an adjunctive medication in post-rain asthma acute phase attack. Adv Respir Med. 2022;90(1):37–48. doi:10.5603/ARM.a2022.0007.
   Web of Science ®Google Scholar
• Zhang J, Zheng J, Huang K, Chen Y, Yang J, Yao W. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12:1753466618769514. doi:10.1177/1753466618769514.
   Web of Science ®Google Scholar